Gottlieb Jens, Capetian Philipp, Hamsen Uwe, Janssens Uwe, Karagiannidis Christian, Kluge Stefan, König Marco, Markewitz Andreas, Nothacker Monika, Roiter Sabrina, Unverzagt Susanne, Veit Wolfgang, Volk Thomas, Witt Christian, Wildenauer René, Worth Heinrich, Fühner Thomas
Klinik für Pneumologie OE 6870, Medizinische Hochschule Hannover, 30625, Hannover, Deutschland.
Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), Deutsches Zentrum für Lungenforschung (DZL), Hannover, Deutschland.
Med Klin Intensivmed Notfmed. 2022 Feb;117(1):4-15. doi: 10.1007/s00063-021-00884-3.
Oxygen is a drug with specific properties, a defined dose-effect range and side effects. In 2015, in a sample of UK hospital patients, 14% were treated with oxygen, of which only 42% had a prescription. Health care workers are often uncertain about the relevance of hypoxemia, and there is limited awareness of the risks of hyperoxemia. Numerous randomized controlled trials on oxygen therapy have recently been published.
As part of the guideline program of the Working Group of Scientific Medical Societies e. V. (AWMF), this S3 guideline was developed with the participation of 10 medical societies on the basis of a literature search up to 02/01/2021. The system of the Oxford Centre for Evidence-Based Medicine (CEBM) (The Oxford 2011 Levels of Evidence) was used to evaluate the literature. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE), and a formal consensus process of recommendations was performed.
The guideline contains 34 evidence-based recommendations on the indication, prescription, monitoring, and discontinuation of oxygen therapy in acute care. The indication for oxygen is mainly hypoxemia. Hypoxemia and hyperoxemia should be avoided, since both increase mortality. The guideline recommends target ranges of oxygen saturation for acute oxygen therapy without differentiating between different diagnoses. Target areas depend on the risk for hypercapnia and ventilation status. The guideline provides an overview of available oxygen delivery systems and contains recommendations for their selection based on patient safety and comfort.
This is the first German guideline on the use of oxygen in acute care. It is aimed at medical professionals who use oxygen in and outside hospitals and is valid until June 30th, 2024.
氧气是一种具有特定性质、明确剂量效应范围和副作用的药物。2015年,在英国医院患者样本中,14%的患者接受了氧气治疗,其中只有42%有处方。医护人员常常不确定低氧血症的相关性,对高氧血症风险的认识也有限。最近发表了许多关于氧疗的随机对照试验。
作为科学医学协会工作组(AWMF)指南计划的一部分,本S3指南是在10个医学协会参与下,基于截至2021年1月2日的文献检索制定的。使用牛津循证医学中心(CEBM)系统(牛津2011证据级别)对文献进行评估。使用推荐分级评估、制定和评价(GRADE)对证据质量进行评估,并对推荐进行正式的共识过程。
该指南包含34条关于急性护理中氧疗的适应症、处方、监测和停用的循证推荐。氧疗的适应症主要是低氧血症。应避免低氧血症和高氧血症,因为两者都会增加死亡率。该指南推荐了急性氧疗的氧饱和度目标范围,而不区分不同诊断。目标范围取决于高碳酸血症风险和通气状态。该指南概述了可用的氧气输送系统,并包含基于患者安全和舒适度进行选择的推荐。
这是德国首部关于急性护理中氧气使用的指南。它针对在医院内外使用氧气的医学专业人员,有效期至2024年6月30日。